Maria Italia, Michela Salvadè, Filippo La Greca, Elisa Zianni, Silvia Pelucchi, Alessio Spinola, Elena Ferrari, Silvana Archetti, Antonella Alberici, Alberto Benussi, Eino Solje, Annakaisa Haapasalo, Dorit Hoffmann, Kasper Katisko, Johanna Krüger, Roberta Facchinetti, Caterina Scuderi, Alessandro Padovani, Monica DiLuca, Diego Scheggia, Barbara Borroni, Fabrizio Gardoni
Autoantibodies directed against the GluA3 subunit (anti-GluA3 hIgGs) of AMPA receptors have been identified in 20%-25% of patients with frontotemporal lobar degeneration (FTLD). Data from patients and in vitro/ex vivo pre-clinical studies indicate that anti-GluA3 hIgGs negatively affect glutamatergic neurotransmission. However, whether and how the chronic presence of anti-GluA3 hIgGs triggers synaptic dysfunctions and the appearance of FTLD-related neuropathological and behavioural signature has not been clarified yet...
March 12, 2024: Brain, Behavior, and Immunity